Pembrolizumab in Metastatic Anal Cancer

NCT02919969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Anal Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]